Open Menu Close Menu Open Search Close Search Open Directory Close Directory

Heather L. Gardner - DVM, PhD, DACVIM (Oncology)

Heather L. Gardner
Assistant Research Professor

Campus Phone:

Heather Gardner, DVM, DACVIM (Oncology) is an assistant research professor at the Cummings School of Veterinary Medicine at Tufts University. Her laboratory efforts center on comparative and translational oncology, using the tumor genome to inform novel therapeutic approaches.

Dr. Gardner earned her DVM at Washington State University and completed her Residency in Medical Oncology at the Ohio State University before completing her PhD in Genetics at Tufts University.



  • PhD – Tufts University, 2020
  • DVM – Washington State University, 2011
  • BS – Washington State University, 2005

Board Certification

  • DACVIM (Oncology) – 2017
  1. Somarelli, J.A., Gardner, H., Cannataro, V.L., Gunady, E.F., Boddy, A.M., Johnson, N.A., Fisk, J.N., Gaffney, S.G., Chuang, J.H., Li, S., Ciccarelli, F.D., Panchenko, A.R., Megquier, K., Kumar, S., Dornburg, A., Degregori, J., Townsend, J.P. 2020. Molecular Biology and Evolution of Cancer: From Discovery to Action. Molecular Biology and Evolution.
  2. Somarelli, J.A., Boddy, A.M., Gardner, H.L., Dewitt, S.B., Tuohy, J., Megquier, K., Sheth, M.U., Hsu, S.D., Thorne, J.L., London, C.A., Eward, W.C. 2020. Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life. Molecular Biology and Evolution.
  3. Kwong, M., Gardner, H.L., Dieterle, N., Rentko, V. 2019. Optimization of Electronic Medical Records for Data Mining Using a Common Data Model. Topics in Companion Animal Medicine.
  4. Kwong, M., Gardner, H.L., Dieterle, N., Rentko, V. 2019. TRANSLATOR Database—A Vision for a Multi-Institutional Research Network. Topics in Companion Animal Medicine.
  5. Gardner, H.L., Sivaprakasam, K., Briones, N., Zismann, V., Perdigones, N., Drenner, K., Facista, S., Richholt, R., Liang, W., Aldrich, J., Trent, J.M., Shields, P.G., Robinson, N., Johnson, J., Lana, S., Houghton, P., Fenger, J., Lorch, G., Janeway, K.A., London, C.A., Hendricks, W.P.D. 2019. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Communications Biology.
  6. Barrett, L.E., Gardner, H.L., Barber, L.G., Sadowski, A., London, C.A. 2019. Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: A pilot study. BMC Veterinary Research.
  7. Gardner, H.L., Londhe, P., London, C.A. 2019. Leveraging dogs with spontaneous cancer to advance drug development. Animal Models in Cancer Drug Discovery.
  8. Alexander, C.K., Cronin, K.L., Silver, M., Gardner, H.L., London, C. 2019. The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma. Journal of Small Animal Practice.
  9. London, C.A., Acquaviva, J., Smith, D.L., Sequeira, M., Ogawa, L.S., Gardner, H.L., Bernabe, L.F., Bear, M.D., Bechtel, S.A., Proia, D.A. 2018. Consecutive day Hsp90 inhibitor administration improves efficacy in murine models of KIT-driven malignancies and canine mast cell tumors. Clinical Cancer Research.
  10. Sadowski, A.R., Gardner, H.L., Borgatti, A., Wilson, H., Vail, D.M., Lachowicz, J., Manley, C., Turner, A., Klein, M.K., Waite, A., Sahora, A., London, C.A. 2018. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Veterinary Research.
  11. Gardner, H.L., Rippy, S.B., Bear, M.D., Cronin, K.L., Heeb, H., Burr, H., Cannon, C.M., Penmetsa, K.V., Viswanadha, S., Vakkalanka, S., London, C.A. 2018. Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma. PLoS ONE.
  12. Schuh, E.M., Portela, R., Gardner, H.L., Schoen, C., London, C.A. 2017. Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Veterinary Research.
  13. Yu, P.Y., Gardner, H.L., Roberts, R., Cam, H., Hariharan, S., Ren, L., Leblanc, A.K., Xiao, H., Lin, J., Guttridge, D.C., Mo, X., Bennett, C.E., Coss, C.C., Ling, Y., Phelps, M.A., Houghton, P., London, C.A. 2017. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing’s sarcoma, and rhabdomyosarcoma. PLoS ONE.
  14. London, C.A., Gardner, H.L., Rippy, S., Post, G., La Perle, K., Crew, L., Lopresti-Morrow, L., Garton, A.J., McMahon, G., LaVallee, T.M., Gedrich, R. 2017. KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells. Clinical Cancer Research.
  15. Rippy, S.B., Gardner, H.L., Nguyen, S.M., Warry, E.E., Portela, R.F., Drost, W.T., Hostnik, E.T., Green, E.M., Chew, D.J., Peng, J., London, C.A. 2016. Erratum to: A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma [BMC Vet Res, 12 (2016) (257)], DOI: 10.1186/s12917-016-0882-6. BMC Veterinary Research.
  16. Rippy, S.B., Gardner, H.L., Nguyen, S.M., Warry, E.E., Portela, R.A., Drost, W.T., Hostnik, E.T., Green, E.M., Chew, D.J., Peng, J., London, C.A. 2016. A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. BMC Veterinary Research.
  17. Randall, V.D., Boston, S.E., Gardner, H.L., Griffin, L., Oblak, M.L., Kubicek, L. 2016. Pubectomy and stereotactic radiotherapy for the treatment of a non-resectable sacral osteosarcoma causing pelvic canal obstruction in a dog. Canadian Veterinary Journal.
  18. Harrington, B.K., Gardner, H.L., Izumi, R., Hamdy, A., Rothbaum, W., Coombes, K.R., Covey, T., Kaptein, A., Gulrajani, M., Van Lith, B., Krejsa, C., Coss, C.C., Russell, D.S., Zhang, X., Urie, B.K., London, C.A., Byrd, J.C., Johnson, A.J., Kisseberth, W.C. 2016. Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-hodgkin lymphoma. PLoS ONE.
  19. Gardner, H.L., Fenger, J.M., London, C.A. 2016. Dogs as a model for cancer. Annual Review of Animal Biosciences.
  20. Cam, M., Gardner, H.L., Roberts, R.D., Fenger, J.M., Guttridge, D.C., London, C.A., Cam, H. 2016. ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma. Oncotarget.

General Research Interests

  • Comparative and Translational Oncology
  • Osteosarcoma
  • Targeted Therapeutics
  • Comparative Genomics
  • Molecular Oncology

Selected Research Projects

  • Defining the functional consequences and therapeutic vulnerability of dystrophin alterations in canine osteosarcoma.
  • Characterizing the role of SETD2 mutations in osteosarcoma.
  • Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma.

Research and Clinical Interests

  • Use of spontaneous tumors in dogs as a model for human cancers
  • Employing comparative genomics to investigate novel therapeutic targets